Complete Guide to Population Vancomycin Model Pharmacokinetics
Overview
Population Vancomycin Model is a Glycopeptide antibiotic used in the Infectious Disease therapeutic area. It is indicated for Suspected or confirmed Staphylococcus aureus infections in extremely obese adults. Interactive vancomycin population pharmacokinetic simulator based on Adane et al. 2015 for extremely obese adults, with weight-based volume, creatinine-clearance-based clearance, AUC24 guidance, and trough monitoring context.
Mechanism of Action
Population Vancomycin Model exerts its pharmacological effect by targeting Vancomycin exposure in extreme obesity. As a Glycopeptide antibiotic, it modulates this target to achieve therapeutic efficacy in Suspected or confirmed Staphylococcus aureus infections in extremely obese adults. Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
The following parameters are derived from published One-compartment PopPK IV infusion models for Population Vancomycin Model:
| Parameter | Value |
|---|---|
| route | Intravenous infusion |
| t half | approximately 8 hours |
| target | AUC24/MIC >= 400 and trough 10-20 mg/L |
| cl ref l h | 6.54 |
| v equation | V = 0.51 x TBW |
| v l per kg | 0.51 |
| cl equation | CL = 6.54 x (Clcr / 125) |
| median auc24 mg h l | 582.9 |
| reference weight kg | 147.9 |
| reference clcr ml min 1 73m2 | 125 |
Parameters represent typical population estimates from published literature. Individual values may vary.
Dosing & Administration
Population Vancomycin Model is administered via the Intravenous infusion route. Intravenous administration provides 100% bioavailability and allows precise control of drug exposure. Infusion duration and rate can significantly impact peak concentrations.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Infectious Disease therapeutic area, for the treatment of Suspected or confirmed Staphylococcus aureus infections in extremely obese adults, understanding the pharmacokinetics of Population Vancomycin Model is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect Population Vancomycin Model pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
Interactive Population Vancomycin Model PK Simulator
Explore Population Vancomycin Model pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of Population Vancomycin Model?
The elimination half-life of Population Vancomycin Model depends on patient-specific factors. Based on published models, the typical half-life is approximately approximately 8 hours.
How is Population Vancomycin Model administered?
Population Vancomycin Model is administered via the Intravenous infusion route. It is indicated for Suspected or confirmed Staphylococcus aureus infections in extremely obese adults. As a Glycopeptide antibiotic, dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of Population Vancomycin Model?
Key pharmacokinetic parameters for Population Vancomycin Model include clearance (CL), volume of distribution (Vd), and elimination half-life. See the PK Parameters section above for specific values from published models.
Can I simulate Population Vancomycin Model dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive Population Vancomycin Model PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.